Insider · CIK 0001734919
Shirley R. Kuhlmann
Files at COLL (COLLEGIUM PHARMACEUTICAL, INC). First filing Nov 29, 2023, latest Mar 6, 2025.
In brief
Shirley R. Kuhlmann files SEC Form 4 as officer at COLL (COLLEGIUM PHARMACEUTICAL, INC). Since Nov 29, 2023, Shirley R. Kuhlmann has reported 0 open-market buys worth $0 and 3 open-market sells worth $4.0M, the latest filed on Mar 6, 2025.
A track record needs three past buys with six months of prices behind them; Shirley R. Kuhlmann has 0, so none is measured yet.
The newest scored trade: sold $2.4M of COLL on Mar 4, 2025, filed Mar 6, 2025, scored 50 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
COLL: COLLEGIUM PHARMACEUTICAL, INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | COLLEGIUM PHARMACEUTICAL, INC | $2.4M 86,067 shares | -44% | - | |
| 9Weak | COLLEGIUM PHARMACEUTICAL, INC | $909k 27,500 shares | -19% | - | |
| 5Weak | COLLEGIUM PHARMACEUTICAL, INC | $660k 25,600 shares | -18% | +23% from low-13% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 20, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | 40,494 0.13% of outstanding | $1.2M | Mar 20, 2025 | $3.3M |
| Mar 6, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | 26,067 0.08% of outstanding | $743k | Mar 6, 2025 | $2.6M |
| Mar 5, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | 20,000 0.06% of outstanding | $561k | Mar 5, 2025 | $2.0M |
| Mar 4, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | 40,000 0.13% of outstanding | $1.1M | Mar 4, 2025 | $909k |
| Jan 10, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | 27,500 0.09% of outstanding | $909k | Jan 10, 2025 | none |
| Nov 27, 2023 | COLL COLLEGIUM PHARMACEUTICAL, INC | 25,600 0.08% of outstanding | $660k | Nov 27, 2023 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 4, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | MOption exercise Common Stock | +40,000 | $24.03 | $961k | 194,204 | Mar 6, 2025 |
| Mar 4, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | SOpen-market sale Common Stock | -40,000 | $28.08 | $1.1M | 154,204 | Mar 6, 2025 |
| Mar 5, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | SOpen-market sale Common Stock | -20,000 | $28.03 | $561k | 134,204 | Mar 6, 2025 |
| Mar 6, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | SOpen-market sale Common Stock | -26,067 | $28.50 | $743k | 108,137 | Mar 6, 2025 |
| Mar 4, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | MOption exercise Stock Option (Right to Purchase)derivative | -40,000 | $0.00 | $0 | 0 | Mar 6, 2025 |
| Feb 10, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | AGrant or award Common Stock | +40,965 | $0.00 | $0 | 160,149 | Feb 12, 2025 |
| Feb 10, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | AGrant or award Common Stock | +29,030 | $0.00 | $0 | 189,179 | Feb 12, 2025 |
| Feb 10, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | FTax withholding Common Stock | -9,826 | $30.52 | $300k | 179,353 | Feb 12, 2025 |
| Feb 10, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | FTax withholding Common Stock | -25,149 | $30.52 | $768k | 154,204 | Feb 12, 2025 |
| Jan 10, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | MOption exercise Common Stock10b5-1 | +27,500 | $21.34 | $587k | 146,684 | Jan 14, 2025 |
| Jan 10, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | SOpen-market sale Common Stock10b5-1 | -21,400 | $32.87 | $703k | 125,284 | Jan 14, 2025 |
| Jan 10, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | SOpen-market sale Common Stock10b5-1 | -6,100 | $33.64 | $205k | 119,184 | Jan 14, 2025 |
| Jan 10, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | MOption exercise Stock Option (Right to Purchase)derivative10b5-1 | -27,500 | $0.00 | $0 | 0 | Jan 14, 2025 |
| Feb 12, 2024 | COLL COLLEGIUM PHARMACEUTICAL, INC | AGrant or award Common Stock | +43,400 | $0.00 | $0 | 162,918 | Feb 14, 2024 |
| Feb 12, 2024 | COLL COLLEGIUM PHARMACEUTICAL, INC | AGrant or award Common Stock | +33,247 | $0.00 | $0 | 196,165 | Feb 14, 2024 |
| Feb 12, 2024 | COLL COLLEGIUM PHARMACEUTICAL, INC | FTax withholding Common Stock | -21,146 | $33.70 | $713k | 175,019 | Feb 14, 2024 |
| Feb 12, 2024 | COLL COLLEGIUM PHARMACEUTICAL, INC | FTax withholding Common Stock | -10,610 | $33.70 | $358k | 164,409 | Feb 14, 2024 |
| Nov 27, 2023 | COLL COLLEGIUM PHARMACEUTICAL, INC | MOption exercise Common Stock10b5-1 | +25,600 | $15.90 | $407k | 145,118 | Nov 29, 2023 |
| Nov 27, 2023 | COLL COLLEGIUM PHARMACEUTICAL, INC | SOpen-market sale Common Stock10b5-1 | -25,600 | $25.78 | $660k | 119,518 | Nov 29, 2023 |
| Nov 27, 2023 | COLL COLLEGIUM PHARMACEUTICAL, INC | MOption exercise Stock Option (Right to Purchase)derivative10b5-1 | -25,600 | $0.00 | $0 | 0 | Nov 29, 2023 |
Questions about Shirley R. Kuhlmann
Answered from the filings on this page, as of the latest one.
Is Shirley R. Kuhlmann buying or selling?
Not in the last 12 months. Shirley R. Kuhlmann's latest open-market trade on SEC Form 4 was sold $2.4M of COLL on Mar 4, 2025.
How did Shirley R. Kuhlmann's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Shirley R. Kuhlmann has 0.
Where does Shirley R. Kuhlmann file Form 4?
Shirley R. Kuhlmann has filed Form 4 at COLL (COLLEGIUM PHARMACEUTICAL, INC) as EVP and General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.